NDLI: Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

Please wait, while we are loading the content...

Early versus conventional switching of antidepressant: a post-hoc analysis of clinical trial data for major depressive disorder with moderate to severe pain symptoms.

Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.

Atorvastatin calcium plus amlodipine for the treatment of hypertension.

Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients.

New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.

Current pharmacotherapy options for gastritis.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.

Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?

New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.

Year: 2012 Volume: 13 Issue: 17

Year: 2012 Volume: 13 Issue: 16

Year: 2012 Volume: 13 Issue: 15

Year: 2012 Volume: 13 Issue: 14

Year: 2012 Volume: 13 Issue: 13

Year: 2012 Volume: 13 Issue: 12

Year: 2012 Volume: 13 Issue: 11

Year: 2012 Volume: 13 Issue: 10

Year: 2012 Volume: 13 Issue: 9

Year: 2012 Volume: 13 Issue: 8

Year: 2012 Volume: 13 Issue: 7

Year: 2012 Volume: 13 Issue: 6

Year: 2012 Volume: 13 Issue: 5

Year: 2012 Volume: 13 Issue: 4

Year: 2012 Volume: 13 Issue: 3

Year: 2012 Volume: 13 Issue: 2

Year: 2012 Volume: 13 Issue: 1

Year: 2011 Volume: 12

Year: 2010 Volume: 11

Year: 2009 Volume: 10

Year: 2008 Volume: 9

Year: 2006 Volume: 7

Year: 2004 Volume: 5

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Tocci, Giuliano Paneni, Francesco Passerini, Jasmine Volpe, Massimo
Description	Country affiliation: Italy Author Affiliation: Tocci G ( IRCCS Neuromed, Pozzilli, Italy.)
Abstract	INTRODUCTION: Effective treatment of hypertension is a key strategy for preventing and reducing the burden of hypertension-related cardiovascular diseases. In spite of these well-established concepts, hypertension remains poorly controlled, worldwide. Among the different pharmacological strategies required to improve blood pressure (BP) control, a more extensive use of combination therapy is progressively emerging as a cornerstone of a more effective treatment of hypertension. Among different drug combinations currently available for the clinical management of hypertension, those based on the association of drugs inhibiting the renin-angiotensin system, thiazide diuretics and calcium channel blockers have demonstrated to be very effective in lowering both systolic and diastolic, clinic and 24-h ambulatory BP levels with a good tolerability and safety profile. AREAS COVERED: In the present manuscript the authors provide an overview of the evidence supporting the use of triple combination therapy with different classes of antihypertensive drugs, with a particular focus on those based on olmesartan medoxomil, a thiazide diuretic (hydrochlorothiazide) and a calcium channel blocker (amlodipine besylate). EXPERT OPINION: Available data indicate that triple combination therapy based on olmesartan provides effective and sustained clinical and 24-h BP control in a high proportion of individuals among a broad range of hypertensive patients.
File Format	HTM / HTML
ISSN	14656566
Issue Number	18
Volume Number	13
e-ISSN	17447666
Journal	Expert Opinion on Pharmacotherapy
Language	English
Publisher	Taylor & Francis
Publisher Date	2012-12-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Amlodipine Therapeutic Use Antihypertensive Agents Hydrochlorothiazide Hypertension Drug Therapy Imidazoles Tetrazoles Adverse Effects Angiotensin Ii Type 1 Receptor Blockers Animals Calcium Channel Blockers Clinical Trials As Topic Diuretics Drug Therapy, Combination Evidence-based Medicine Humans Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.

Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.

Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.

Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.

Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension.

Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study.

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

Similar Documents

Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.

Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.

Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.

Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.

Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension.

Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study.

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.